BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement

ANAHEIM, CA, March 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance abuse disorders, today announced that it has promoted Dr. Balbir S. Brar to Senior VP of Drug Development and extended his agreement for an additional one year period. 

Brady Granier, President, CEO and Director, stated, “We appreciate Dr. Brar’s guidance and expertise which has been extremely valuable as we continue to move forward with our plans for BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders, as well as other products in our pipeline. We were recently awarded a grant from National Institute on Drug Abuse (NIDA) and we are advancing the development process for our lead pharmaceutical candidate, BICX102.  Dr. Brar has made significant contributions throughout this whole process and we appreciate his continued support.” 

Dr. Brar, Senior VP of Drug Development, commented, “I look forward to helping further advance and accelerate the regulatory approval process for BICX102. The fact that BioCorRx was awarded the NIDA grant is a validation that BICX102 is much needed in this underserved marketplace with few viable treatment options for patients.”

Dr. Brar has over 25 years of experience in drug and device development, including worldwide regulatory submissions for over 50 INDs, 510(k)s and 505(b)(2)s, as well as approval of 8 NDAs for drugs currently on the market. Dr. Brar’s experience includes working with major pharmaceutical companies such as Lederle/Wyeth, where he was instrumental in the development of Azmacort for asthma, as well as topical Aristocort. At GlaxoSmithKline, as Director of Drug Safety, Dr. Brar participated in the development of Tazarotene. At Allergan, as VP of Drug Safety, he made major contributions towards the development, regulatory submission, and approval of Botox, Alphagan, Lumigan, Restasis, Ofloxacin, Azelex, and Avage.

For the past 10 years Dr. Brar has played a leadership role for several early stage biotechnology companies in the fields of nephropathy, oncology, ophthalmology, dermatology, pain, and cardiology. During this time, Dr. Brar served on the Board of Directors, and acted as President, EVP R&D, and Chief Technology Officer. Dr. Brar has a Ph.D. in Toxicology/Pathology from Rutgers University and D.V.M. from a university in India with finance training from Harvard Business School. 

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, and can prevent opioid overdose following relapse. The second component of the program developed by BioCorRx Inc. is a Cognitive Behavioral Therapy (CBT) program tailored specifically for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, visit 

Twitter:             @BioCorRxInc 


Facebook:        @BioCorRx

Instagram:       @biocorrx_inc

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304


Source: BioCorRx Inc